Preclinical evaluation of the immunomodulatory properties of cardiac adipose tissue progenitor cells using umbilical cord blood mesenchymal stem cells: A direct comparative study

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Perea Gil, Isaac ^a   Monguió Tortajada, Marta ^a   Gálvez Montón, Carolina ^a   Bayes Genis, Antoni ^a,b,c   Borràs, Francesc E ^a,b   Roura, Santiago ^a  

^a FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; ENDOGLIN; FAT DROPLET; GAMMA INTERFERON; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; THY 1 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; IMMUNOLOGIC FACTOR;

ADIPOSE TISSUE; ADULT; ARTICLE; CARDIAC ADIPOSE TISSUE PROGENITOR CELL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; COCULTURE; COMPARATIVE STUDY; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MONOCYTE; PRIMARY CULTURE; T LYMPHOCYTE; UMBILICAL CORD BLOOD; ANTIBODY PRODUCTION; CELL CULTURE; FETUS BLOOD; HEART; IMMUNOLOGY; MESENCHYMAL STROMA CELL; PHYSIOLOGY; PROCEDURES; STEM CELL; UMBILICAL CORD;

ADIPOSE TISSUE; ANTIBODY FORMATION; CELLS, CULTURED; COCULTURE TECHNIQUES; FETAL BLOOD; HEART; HUMANS; IMMUNOLOGIC FACTORS; MESENCHYMAL STROMAL CELLS; STEM CELLS; T-LYMPHOCYTES; UMBILICAL CORD;

EID: 84925679883     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/439808     Document Type: Article

References (43)

1. H. M. Blau, T. R. Brazelton, and J. M.Weimann, "The evolving concept of a stem cell: entity or function?" Cell, vol. 105, no. 7, pp. 829-841, 2001.
2. G. Q. Daley, "The promise and perils of stem cell therapeutics," Cell Stem Cell, vol. 10, no. 6, pp. 740-749, 2012.
3. H. Main, M. Munsie, and M. D. O'Connor, "Managing the potential and pitfalls during clinical translation of emerging stem cell therapies," Clinical and Translational Medicine, vol. 3, article 10, 2014.
4. G.Olivetti, J. M. Capasso, L. G.Meggs, E. H. Sonnenblick, and P. Anversa, "Cellular basis of chronic ventricular remodeling after myocardial infarction in rats," Circulation Research, vol. 68, no. 3, pp. 856-869, 1991.
5. A. P. Beltrami, L. Barlucchi, D. Torella et al., "Adult cardiac stem cells are multipotent and support myocardial regeneration," Cell, vol. 114, no. 6, pp. 763-776, 2003.
6. H. Oh, S. B. Bradfute, T. D. Gallardo et al., "Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction," Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 21, pp. 12313-12318, 2003.
7. C. Soler-Botija, J. R. Bagó, and A. Bayes-Genis, "A bird'seye view of cell therapy and tissue engineering for cardiac regeneration," Annals of the New York Academy of Sciences, vol. 1254, no. 1, pp. 57-65, 2012.
8. A. Bayes-Genis, C. Soler-Botija, J. Farŕe et al., "Human progenitor cells derived from cardiac adipose tissue ameliorate myocardial infarction in rodents," Journal of Molecular and Cellular Cardiology, vol. 49, no. 5, pp. 771-780, 2010.
9. M. Lee, S. Y. Jeong, J. Ha et al., "Low immunogenicity of allogeneic human umbilical cord blood-derived mesenchymal stem cells in vitro and in vivo," Biochemical and Biophysical Research Communications, vol. 446, no. 4, pp. 983-989, 2014.
10. C. Prat-Vidal, S. Roura, J. Farŕe et al., "Umbilical cord bloodderived stem cells spontaneously express cardiomyogenic traits," Transplantation Proceedings, vol. 39,no. 7, pp. 2434-2437, 2007.
11. S. Roura, J. Farŕe, L. Hove-Madsen et al., "Exposure to cardiomyogenic stimuli fails to transdifferentiate human umbilical cord blood-derived mesenchymal stem cells," Basic Research in Cardiology, vol. 105, no. 3, pp. 419-430, 2010.
12. S. Roura, J. R. Bagó, C. Soler-Botija et al., "Human umbilical cord blood-derived mesenchymal stem cells promote vascular growth in vivo," PLoS ONE, vol. 7, no. 11,Article IDe49447, 2012.
13. M. Naranjo-Gómez, N. Climent, J. Cos et al., "Tacrolimus treatment of plasmacytoid dendritic cells inhibits dinucleotide (CpG-)-induced tumour necrosis factor-alpha secretion," Immunology, vol. 119, no. 4, pp. 488-498, 2006.
14. L. Badimon and G. Vilahur, "Experimental cell therapy: the search for the best stem cell continues," Journal of the American College of Cardiology, vol. 64, pp. 1695-1697, 2014.
15. H. S. Sacks and J. N. Fain, "Human epicardial adipose tissue: a review,"The American Heart Journal, vol. 153, no. 6, pp. 907-917, 2007.
16. P. Comoli, F. Ginevri, R.Maccario et al., "Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation," Nephrology Dialysis Transplantation, vol. 23, no. 4, pp. 1196-1202, 2008.
17. G. Chamberlain, J. Fox, B. Ashton, and J. Middleton, "Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing," Stem Cells, vol. 25, no. 11, pp. 2739-2749, 2007.
18. S. Aggarwal and M. F. Pittenger, "Human mesenchymal stem cells modulate allogeneic immune cell responses," Blood, vol. 105, no. 4, pp. 1815-1822, 2005.
19. M. D. Nicola, C. Carlo-Stella, M. Magni et al., "Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli," Blood, vol. 99, no. 10, pp. 3838-3843, 2002.
20. A. Bartholomew, C. Sturgeon,M. Siatskas et al., "Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo," Experimental Hematology, vol. 30, no. 1, pp. 42-48, 2002.
21. W. T. Tse, J. D. Pendleton, W. M. Beyer, M. C. Egalka, and E. C. Guinan, "Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation," Transplantation, vol. 75, no. 3, pp. 389-397, 2003.
22. K. le Blanc, I. Rasmusson, B. Sundberg et al., "Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells," The Lancet, vol. 363, no. 9419, pp. 1439-1441, 2004.
23. O. Ringdén, M. Uzunel, I. Rasmusson et al., "Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease," Transplantation, vol. 81, no. 10, pp. 1390-1397, 2006.
24. M. Krampera, L. Cosmi, R. Angeli et al., "Role for interferon- .. in the immunomodulatory activity of human bone marrow mesenchymal stem cells," Stem Cells, vol. 24, no. 2, pp. 386-398, 2006.
25. R. Herrmann, M. Sturm, K. Shaw et al., "Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study," International Journal of Hematology, vol. 95, no. 2, pp. 182-188, 2012.
26. M. J. Hoogduijn, M. Roemeling-Van Rhijn, A. U. Engela et al., "Mesenchymal stem cells induce an inflammatory response after intravenous infusion," Stem Cells and Development, vol. 22, no. 21, pp. 2825-2835, 2013.
27. M. J. Crop, C. C. Baan, S. S. Korevaar, J. N. M. Ijzermans, W. Weimar, and M. J. Hoogduijn, "Human adipose tissue-derived mesenchymal stem cells induce explosive T-Cell proliferation," Stem Cells and Development, vol. 19, no. 12, pp. 1843-1853, 2010.
28. A. J.Nauta,G.Westerhuis, A. B. Kruisselbrink, E. G. A. Lurvink, R. Willemze, and W. E. Fibbe, "Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting," Blood, vol. 108, no. 6, pp. 2114-2120, 2006.
29. P. Sbano, A. Cuccia, B. Mazzanti et al., "Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model," Archives of Dermatological Research, vol. 300, no. 3, pp. 115-124, 2008.
30. P. Kebriaei and S. Robinson, "Mesenchymal stem cell therapy in the treatment of acute and chronic graft versus host disease," Frontiers in Oncology, vol. 1, article 16, 2011.
31. E. Gluckman, "Milestones in umbilical cord blood transplantation," Blood Reviews, vol. 25, no. 6, pp. 255-259, 2011.
32. S. Roura, J.-M. Pujal, and A. Bayes-Genis, "Umbilical cord blood for cardiovascular cell therapy: from promise to fact," Annals of the New York Academy of Sciences, vol. 1254, no. 1, pp. 66-70, 2012.
33. A. J. Cutler, V. Limbani, J. Girdlestone, and C. V. Navarrete, "Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation," The Journal of Immunology, vol. 185, no. 11, pp. 6617-6623, 2010.
34. H. Mayani and P. M. Lansdorp, "Biology of human umbilical cord blood-derived hematopoietic stem/progenitor cells," Stem Cells, vol. 16, no. 3, pp. 153-165, 1998.
35. H.Mayani, "Umbilical cord blood: lessons learned and lingering challenges after more than 20 years of basic and clinical research," Archives of Medical Research, vol. 42, no. 8, pp. 645- 651, 2011.
36. K. Le Blanc, L. Tammik, B. Sundberg, S. E.Haynesworth, andO. Ringdén, "Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures andmitogenic responses independently of the major histocompatibility complex," Scandinavian Journal of Immunology, vol. 57, no. 1, pp. 11-20, 2003.
37. S. M. Melief, J. J. Zwaginga, W. E. Fibbe, and H. Roelofs, "Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts," Stem Cells Translational Medicine, vol. 2, no. 6, pp. 455-463, 2013.
38. R. Meisel, A. Zibert, M. Laryea, U. Göbel, W. Däubener, and D. Dilloo, "Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation," Blood, vol. 103, no. 12, pp. 4619-4621, 2004.
39. A. Augello, R. Tasso, S. M. Negrini et al., "Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway," European Journal of Immunology, vol. 35, no. 5, pp. 1482-1490, 2005.
40. F. Benvenuto, S. Ferrari, E. Gerdoni et al., "Human mesenchymal stem cells promote survival of T cells in a quiescent state," Stem Cells, vol. 25, no. 7, pp. 1753-1760, 2007.
41. G. Iacobellis and A. C. Bianco, "Epicardial adipose tissue: emerging physiological, pathophysiological and clinical features," Trends in Endocrinology and Metabolism, vol. 22, no. 11, pp. 450-457, 2011.
42. R. M. Agra, E. Teijeira-Ferńandez, D. Pascual-Figal et al., "Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients," European Journal of Clinical Investigation, vol. 44, no. 1, pp. 29-37, 2014.
43. M. Monguío-Tortajada, R. Lauzurica-Valdemoros, and F. E. Borràs, "Tolerance in organ transplantation: from conventional immunosuppression to extracellular vesicles," Frontiers in Immunology, vol. 5, article 416, 2014.